LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has LifeTech Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1302 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 1302's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
7 Day Return
HK Medical Equipment
1 Year Return
HK Medical Equipment
Return vs Industry: 1302 exceeded the Hong Kong Medical Equipment industry which returned 113.9% over the past year.
Return vs Market: 1302 exceeded the Hong Kong Market which returned 15.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is LifeTech Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDoes LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?
1 month ago | Simply Wall StAre Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?
2 months ago | Simply Wall StDo Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?
Is LifeTech Scientific undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1302 (HK$5.46) is trading above our estimate of fair value (HK$1.93)
Significantly Below Fair Value: 1302 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1302 is poor value based on its PE Ratio (139x) compared to the HK Medical Equipment industry average (29.9x).
PE vs Market: 1302 is poor value based on its PE Ratio (139x) compared to the Hong Kong market (11.9x).
Price to Earnings Growth Ratio
PEG Ratio: 1302 is poor value based on its PEG Ratio (6.3x)
Price to Book Ratio
PB vs Industry: 1302 is overvalued based on its PB Ratio (15.6x) compared to the HK Medical Equipment industry average (3.9x).
How is LifeTech Scientific forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1302's forecast earnings growth (22% per year) is above the savings rate (1.5%).
Earnings vs Market: 1302's earnings (22% per year) are forecast to grow faster than the Hong Kong market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1302's revenue (20.2% per year) is forecast to grow faster than the Hong Kong market (14.4% per year).
High Growth Revenue: 1302's revenue (20.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1302's Return on Equity is forecast to be low in 3 years time (14.5%).
How has LifeTech Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1302 has high quality earnings.
Growing Profit Margin: 1302's current net profit margins (21.4%) are lower than last year (23.6%).
Past Earnings Growth Analysis
Earnings Trend: 1302 has become profitable over the past 5 years, growing earnings by 13.4% per year.
Accelerating Growth: 1302's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1302 had negative earnings growth (-7%) over the past year, making it difficult to compare to the Medical Equipment industry average (17.7%).
Return on Equity
High ROE: 1302's Return on Equity (10.3%) is considered low.
How is LifeTech Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: 1302's short term assets (CN¥628.6M) exceed its short term liabilities (CN¥474.9M).
Long Term Liabilities: 1302's short term assets (CN¥628.6M) exceed its long term liabilities (CN¥144.5M).
Debt to Equity History and Analysis
Debt Level: 1302's debt to equity ratio (29.9%) is considered satisfactory.
Reducing Debt: 1302 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: 1302's debt is well covered by operating cash flow (70.6%).
Interest Coverage: 1302's interest payments on its debt are well covered by EBIT (17.2x coverage).
What is LifeTech Scientific current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1302's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1302's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1302's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1302's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1302 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1302's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yuehui Xie (51 yo)
Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo...
CEO Compensation Analysis
Compensation vs Market: Yuehui's total compensation ($USD2.51M) is above average for companies of similar size in the Hong Kong market ($USD687.78K).
Compensation vs Earnings: Yuehui's compensation has been consistent with company performance over the past year.
|Chairman & CEO||5.83yrs||CN¥16.25m||16.9% |
|CFO, Executive VP||5.83yrs||CN¥12.99m||0.18% |
|Independent Non-Executive Director||9.25yrs||CN¥108.00k||no data|
|Independent Non-Executive Director||6.75yrs||CN¥108.00k||no data|
|Non-Executive Director||6.75yrs||CN¥108.00k||no data|
|Independent Non-Executive Director||5yrs||CN¥108.00k||no data|
|Non-Executive Director||1.42yrs||no data||no data|
Experienced Board: 1302's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.1%.
LifeTech Scientific Corporation's company bio, employee growth, exchange listings and data sources
- Name: LifeTech Scientific Corporation
- Ticker: 1302
- Exchange: SEHK
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$25.263b
- Shares outstanding: 4.63b
- Website: https://www.lifetechmed.com
Number of Employees
- LifeTech Scientific Corporation
- Cybio Electronic Building
- Langshan 2nd Street
- Guangdong Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1302||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Common Shares||HK||HKD||Nov 2011|
|1302||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Common Shares||HK||HKD||Nov 2011|
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 10:14|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.